Adverum Biotechnologies Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 6/5/2025)
| Balance Sheet | Total Assets | 250,546,000.00 | ROE | – |
| Balance Sheet | Total Equity | 163,681,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -388,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -92,850,000.00 | – | – |
| Cashflow | Operating Cash Flow | -92,462,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -6.62 | Div. Yield | – |
| Income | Net Income | -130,927,000.00 | P/E | – |
| Income | Shares Outstanding | 20,848,000.00 | P/B | – |
| Income | Total Revenue | 1,000,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.adverum.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more